Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.

David CharlesJemma ShanleySasha-Nicole TempleAnna RattuEkaterina KhalevaGraham C Roberts

Published in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2022)

These data demonstrate that anti-IL5 biologicals may improve the clinical outcomes of patients with severe asthma in a clinic environment with similar effect sizes to RCTs. The data were mainly retrospective and unadjusted, so estimated effect sizes may not be reliable. More data are needed to acquire accurate effect estimates in different subpopulations of patients.

Keyphrases

electronic health record
end stage renal disease
big data
primary care
ejection fraction
peritoneal dialysis
atopic dermatitis
patient reported
combination therapy